Jazz Pharmaceuticals Overview

  • Founded
  • 2003
Founded
  • Status
  • Public
  • Employees
  • 3,200
Employees
  • Stock Symbol
  • JAZZ
Stock Symbol
  • Investments
  • 16
  • Share Price
  • $142.98
  • (As of Tuesday Closing)

Jazz Pharmaceuticals General Information

Description

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small-cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Other Pharmaceuticals and Biotechnology
Stock Exchange
NAS
Primary Office
  • Waterloo Exchange
  • Waterloo Road
  • Dublin 4
  • Ireland
+353 (01) 000 0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Jazz Pharmaceuticals Stock Performance

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$142.98 $145.50 $117.64 - $189.00 $9.1B 61.7M 578K -$7.51

Jazz Pharmaceuticals Financials Summary

In Thousands,
USD
TTM 31-Mar-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 15,172,343 13,544,144 9,521,342 9,144,316
Revenue 3,300,378 3,094,238 2,363,567 2,161,761
EBITDA 739,098 718,411 653,055 896,719
Net Income (449,853) (329,668) 238,616 523,367
Total Assets 11,768,917 12,298,639 6,535,901 5,538,897
Total Debt 6,123,101 6,152,906 2,249,330 1,771,211
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Jazz Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Jazz Pharmaceuticals‘s full profile, request access.

Request a free trial

Jazz Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorde
Pharmaceuticals
Dublin, Ireland
3,200 As of 2021
00000
000000 - 000 00000

00000000

e cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in cu
000000000000000
Stoughton, MA
000 As of 0000
00000
00000000000 00000

00000000

n ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in
000000000000000
Tarrytown, NY
00000 As of 0000
00000
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Jazz Pharmaceuticals Competitors (8)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Collegium Pharmaceutical Formerly VC-backed Stoughton, MA 000 00000 00000000000 00000
000000000 00000000 Formerly VC-backed Tarrytown, NY 00000 00000 00000000000 00000
0000000 Formerly VC-backed Emeryville, CA 000 00000 000000&0 00000
000000 00000000 Formerly VC-backed Foster City, CA 00000 00.000 000000000 00.000
000000 0000 Angel-Backed San Jose, CA 0000 000000000 - 0000
You’re viewing 5 of 8 competitors. Get the full list »

Jazz Pharmaceuticals Patents

Jazz Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210295971-A1 Sensitive drug distribution systems and methods Pending 23-Mar-2020 0000000000
US-20210290589-A1 Methods of providing solriamfetol therapy to subjects with impaired renal function Granted 19-Mar-2020 0000000000
US-11160779-B2 Methods of providing solriamfetol therapy to subjects with impaired renal function Active 19-Mar-2020 0000000000 00
US-10940133-B1 Methods of providing solriamfetol therapy to subjects with impaired renal function Active 19-Mar-2020 0000000000 00
US-20210186907-A1 Ghb dosing Pending 24-Dec-2019 A61K31/19
To view Jazz Pharmaceuticals’s complete patent history, request access »

Jazz Pharmaceuticals Executive Team (41)

Name Title Board Seat Contact Info
Bruce Cozadd Chief Executive Officer & Chairman
Daniel Swisher Jr. Chief Operating Officer, Operations & President
Renee Gala Chief Financial Officer, Finance & Executive Vice President
Christopher Tovey Chief Operating Officer, Operations & Executive Vice President
Kim Sablich Executive Vice President & General Manager
You’re viewing 5 of 41 executive team members. Get the full list »

Jazz Pharmaceuticals Board Members (24)

Name Representing Role Since
Anne O'Riordan Jazz Pharmaceuticals Board Member 000 0000
Bruce Cozadd Jazz Pharmaceuticals Chief Executive Officer & Chairman 000 0000
Catherine Sohn Self Board Member 000 0000
Heather McSharry Self Board Member 000 0000
Jennifer Cook Self Board Member 000 0000
You’re viewing 5 of 24 board members. Get the full list »

Jazz Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Jazz Pharmaceuticals Investments & Acquisitions (16)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000 29-Jul-2021 00000 0000 000.00 Monitoring Equipment
00 0000000000 05-May-2021 0000000000 00.00 Pharmaceuticals 00000 000
00000000000 0 26-Oct-2020 000000000 0000 Buildings and Property
000000 12-Aug-2019 0000000000 00000 Pharmaceuticals 000000 00
Redx Pharma (Rights, titles, interests and patents of pan-RAF inhibitor program) 10-Jul-2019 Corporate Asset Purchase 00000 Buildings and Property 000000 00
You’re viewing 5 of 16 investments and acquisitions. Get the full list »

Jazz Pharmaceuticals Subsidiaries (3)

Company Name Industry Location Founded
Cavion Pharmaceuticals Charlottesville, VA 2002
00 000000000000000 Pharmaceuticals Cambridge, United Kingdom 0000
0000000 Pharmaceuticals Villa Guardia, Italy 0000
To view Jazz Pharmaceuticals’s complete subsidiaries history, request access »

Jazz Pharmaceuticals Exits (2)

Company Name Exit Date Exit Type Exit Size Status Buyers
0000 000000 12-Jun-2012 000000000000000000 00000 Completed
  • 0000 0000000000000
Prialt 05-May-2010 Merger/Acquisition 00000 Completed
To view Jazz Pharmaceuticals’s complete exits history, request access »